系统综述与Meta分析:生物制剂诱导和维持克罗恩病与溃疡性结肠炎黏膜愈合的对比疗效(对照试验)
该系统综述与Meta分析纳入12项随机对照试验,评估免疫抑制剂、抗TNF或抗整合素单抗对中重度CD或UC黏膜愈合的诱导和维持疗效。在UC中,抗TNF和抗整合素优于安慰剂诱导和维持黏膜愈合,阿达木单抗劣于英夫利西单抗及英夫利西单抗联合硫唑嘌呤;在CD中,英夫利西单抗与阿达木单抗相似。
要点
- 在UC中,抗TNF和抗整合素药物诱导黏膜愈合优于安慰剂(45% vs 30%),维持黏膜愈合也优于安慰剂(33% vs 18%)。
- 在UC网络分析中,阿达木单抗诱导黏膜愈合劣于英夫利西单抗(OR 0.45,95% CrI 0.25-0.82)和英夫利西单抗联合硫唑嘌呤(OR 0.32,95% CrI 0.12-0.84)。
- 在CD中,抗TNF药物维持黏膜愈合优于安慰剂(28% vs 1%,OR 19.71,95% CI 3.51-110.84)。
核心结论
- 抗TNF和抗整合素生物制剂可有效诱导UC黏膜愈合,阿达木单抗劣于英夫利西单抗或联合治疗;在CD中英夫利西单抗与阿达木单抗相似。
研究设计与样本
- 系统综述与Meta分析,纳入12项随机对照试验(CD:2项诱导、4项维持;UC:8项诱导、5项维持)。
- 纳入以黏膜愈合为终点的免疫抑制剂、抗TNF或抗整合素单抗治疗中重度CD或UC的随机对照试验。
- 诱导试验随访6-12周,维持试验随访32-54周。
- 采用贝叶斯网络Meta分析进行成对治疗比较。
主要发现
- 在CD中,抗TNF药物维持黏膜愈合优于安慰剂(28% vs 1%,OR 19.71,95% CI 3.51-110.84)。
- 在UC中,抗TNF和抗整合素药物诱导黏膜愈合优于安慰剂(45% vs 30%),维持黏膜愈合也优于安慰剂(33% vs 18%)。
- 在UC网络分析中,阿达木单抗诱导黏膜愈合劣于英夫利西单抗(OR 0.45,95% CrI 0.25-0.82)和英夫利西单抗联合硫唑嘌呤(OR 0.32,95% CrI 0.12-0.84)。
- 在UC中,维得利珠单抗与抗TNF药物之间无统计学显著成对差异。
- 在CD中,英夫利西单抗与阿达木单抗相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mucosal healing is an important therapeutic endpoint in the management of Crohn's disease (CD) and ulcerative colitis (UC). Limited data exist regarding the comparative efficacy of various therapies in achieving this outcome. AIM: To perform a systematic review and meta-analysis of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis. METHODS: We performed a systematic review and meta-analysis of randomised controlled trials (RCT) examining mucosal healing as an endpoint of immunosuppressives, anti-tumour necrosis factor α (anti-TNF) or anti-integrin monoclonal antibody therapy for moderate-to-severe CD or UC. Pooled effect sizes for induction and maintenance of mucosal healing were calculated and pairwise treatment comparisons evaluated using a Bayesian network meta-analysis. RESULTS: A total of 12 RCTs were included in the meta-analysis (CD - 2 induction, 4 maintenance; UC - 8 induction, 5 maintenance). Duration of follow-up was 6-12 weeks for induction and 32-54 weeks for maintenance trials. In CD, anti-TNFs were more effective than placebo for maintaining mucosal healing [28% vs. 1%, Odds ratio (OR) 19.71, 95% confidence interval (CI) 3.51-110.84]. In UC, anti-TNFs and anti-integrins were more effective than placebo for inducing (45% vs. 30%) and maintaining mucosal healing (33% vs. 18%). In network analysis, adalimumab therapy was inferior to infliximab [OR 0.45, 95% credible interval (CrI) 0.25-0.82] and combination infliximab-azathioprine (OR 0.32, 95% CrI 0.12-0.84) for inducing mucosal healing in UC. There was no statistically significant pairwise difference between vedolizumab and anti-TNF agents in UC. CONCLUSIONS: Anti-TNF and anti-integrin biological agents are effective in inducing mucosal healing in UC, with adalimumab being inferior to infliximab or combination therapy. Infliximab and adalimumab were similar in CD.
引用
- Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017. PMID: 28326566. doi:10.1111/apt.14030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。